Showing 4181-4190 of 10733 results for "".
- GLP-1 Receptor Agonists Not Linked to Increased Melanoma Risk in T2Dhttps://practicaldermatology.com/news/glp-1-receptor-agonists-not-linked-to-increased-melanoma-risk-in-t2d/2488105/GLP-1 receptor agonist (GLP-1RA) therapy was not associated with an increased risk of melanoma among adults with type 2 diabetes (T2D) in a large target trial emulation published in Diabetes, Obesity and Metabolism. GLP-1RA Use and Skin Cancer Risk Investigators used TriN
- Upadacitinib Meets Primary Endpoint in Two Phase 3 Alopecia Areata Trialshttps://practicaldermatology.com/news/upadacitinib-meets-primary-endpoint-in-two-phase-3-alopecia-areata-trials/2488081/New data suggests upadacitinib was associated with significantly greater scalp hair regrowth than placebo among adults and adolescents with severe alopecia areata (AA), according to findings published online August 12 in JAMA Dermatology. The replicate UP-AA1 and UP-AA2 trials enr
- New Photoimmunotherapy Approach Targets T Cells and Tumor Antigenshttps://practicaldermatology.com/news/study-new-photoimmunotherapy-approach-targets-t-cells-and-tumor-antigens/2488067/A new activatable photoimmunotherapy platform may enable more selective depletion of pathogenic cells while limiting inflammatory effects associated with existing PIT approaches, according to new research. Photoimmunotherapy
- Abrocitinib Responses Maintained Through Week 72 in JADE REALhttps://practicaldermatology.com/news/abrocitinib-responses-maintained-through-week-72-in-jade-real/2488053/New research suggests that flexible abrocitinib dosing under conditions designed to simulate clinical practice was associated with improvements through Week 72 among observed patients with moderate-to-severe atopic dermatitis (AD). Researchers for the JADE REAL trial enrolled 312 patients
- Adalimumab Leads Cost-Efficiency Analysis of Approved HS Biologics Across Five Countrieshttps://practicaldermatology.com/news/adalimumab-leads-cost-efficiency-analysis-of-approved-hs-biologics-across-five-countries/2488023/Adalimumab offers the most favorable balance of cost and clinical efficacy among currently approved monoclonal antibody therapies for moderate-to-severe hidradenitis suppurativa (HS), according to a new economic evaluation in JAM
- ASDS Launches Financial, Technology Retreat for Dermatologistshttps://practicaldermatology.com/news/asds-launches-financial-technology-retreat-for-dermatologists/2488019/The American Society for Dermatologic Surgery (ASDS) is broadening its educational portfolio with the debut of $kin in the Game, a new financial and technology literacy retreat designed exclusively for dermatologists. The two-day program, developed in collaboration with Wilmington Trust,
- Tapinarof Demonstrates Consistent Efficacy Across Pediatric and Adult Patients With Atopic Dermatitishttps://practicaldermatology.com/news/tapinarof-demonstrates-consistent-efficacy-across-pediatric-and-adult-patients-with-atopic-dermatitis/2487900/Organon will present new data from a post hoc pooled analysis of the Phase 3 ADORING 1 and ADORING 2 trials at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting in Minneapolis, Minnesota, showing that tapinarof (VTAMA) cream 1% produced early and consistent improvements in patients
- Lebrikizumab Meets Primary Endpoints in Phase 3 ADorable-1 Trial for Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/lebrikizumab-meets-primary-endpoints-in-phase-3-adorable-1-trial-for-pediatric-atopic-dermatitis/2487891/Lebrikizumab demonstrated significant improvements in disease severity and symptoms in infants, children, and adolescents with moderate-to-severe atopic dermatitis (AD), according to Week 16 results from the phase 3 ADorable-1 trial presented at the 2026 Society f
- Psychological Burden of Atopic Dermatitis Appears Greatest in Children and Adolescentshttps://practicaldermatology.com/news/psychological-burden-of-atopic-dermatitis-appears-greatest-in-children-and-adolescents/2487888/Children and adolescents with atopic dermatitis (AD) may experience a greater psychological burden than adults with the disease, according to a systematic review and meta-analysis published in Frontiers in Public Health.¹ However, investigators cautioned
- Farming-Associated Maternal Microbiome Linked With Lower Early Childhood Atopic Diseasehttps://practicaldermatology.com/news/study-farming-associated-maternal-microbiome-linked-with-lower-early-childhood-atopic-disease/2487882/A maternal gut microbiome shaped by a traditional farming lifestyle may help explain the protective effect of prenatal farm exposure against atopic disease in children, according to new research published in Allergy.